Amgen v. Sanofi became the Supreme Court's major modern enablement decision for life-sciences patents.
The Court affirmed that Amgen's functional genus claims to antibodies were not enabled across their full scope, even though the patents disclosed examples and screening methods.
For biotech patent owners, the ruling changed the risk profile of broad functional claiming. The broader the genus, the more the specification must teach the public how to make and use the full claimed range without undue experimentation.
IPDispatch should treat this as foundational law for every later antibody, biologics, and platform-technology enablement story.